Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone Dexborneol Sublingual Tablets for BBB Dysfunction in CADASIL
NCT07692399Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of edaravone dexborneol in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sponsored by Huashan Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT07692399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692399.